<?xml version="1.0" encoding="UTF-8"?>
<p>An important limitation of MR in drug development is that most GWAS datasets pertain to disease 
 <italic>risk</italic> rather than 
 <italic>progression</italic>. In other words, most MR studies to date predict whether an intervention could 
 <italic>prevent</italic> disease, rather than slow or hinder its progression. For example, although MR studies show an inverse relationship between vitamin D levels and multiple sclerosis risk, no significant association has been found with multiple sclerosis severity nor age at onset (
 <xref rid="fcaa031-B74" ref-type="bibr">Rhead 
  <italic>et al.</italic>, 2016
 </xref>).
</p>
